Cipla Q4 FY25 Results: Net Profit Surges 30%; Declares ₹16 Dividend

Pharmaceutical major Cipla Ltd reported strong financial results for the fourth quarter of FY25, with consolidated net profit rising 30.12% YoY to ₹1,221.84 crore, compared to ₹939.04 crore in the same period last year.

Cipla Share Price

Cipla Net profit of Cipla rose 30.12% to Rs 1221.84 crore in the quarter ended March 2025 as against Rs 939.04 crore during the previous quarter ended March 2024. Sales rose 8.47% to Rs 6597.72 crore in the quarter ended March 2025 as against Rs 6082.37 crore during the previous quarter ended March 2024.For the full year,net profit rose 27.93% to Rs 5272.52 crore in the year ended March 2025 as against Rs 4121.55 crore during the previous year ended March 2024. Sales rose 6.68% to Rs 27145.40 crore in the year ended March 2025 as against Rs 25446.63 crore during the previous year ended March 2024.

 Q4FY25 Highlights:

  • Revenue from operations grew 8.5% YoY to ₹6,597.72 crore, up from ₹6,082.37 crore in Q4FY24.

  • Pharmaceuticals segment revenue stood at ₹6,503.63 crore, reflecting an 8.5% YoY increase.

  • Revenue from new ventures jumped 35.44% YoY to ₹288.48 crore.

  • EBITDA rose 17% YoY to ₹1,538 crore, with EBITDA margin improving 150 bps YoY to 22.8%.

Year FY25 Performance:

  • Net profit increased 28% YoY to ₹5,273 crore.

  • Total revenue rose 8% YoY to ₹27,548 crore.

  • EBITDA margin for the full year stood at 25.9%, driven by a strong product mix and operational efficiencies.

“In FY25, we recorded a revenue growth of 8% over last year, with an EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY,”

said Umang Vohra, MD and Global CEO, Cipla.

He also highlighted:

  • Branded prescription therapies outperformed overall market growth.

  • Trade generics returned to growth.

  • Consumer health anchor brands continued to lead their categories.

🌍 Global Market Highlights:

  • US business recorded an all-time high annual revenue of $934 million.

  • One Africa saw a 12% YoY growth in USD terms, supported by strong performance across key markets.

  • Emerging Markets & Europe posted 15% YoY growth, driven by focused regional strategies.

💰 Dividend Announcement:

  • A final dividend of ₹13 per equity share for FY25

  • A special dividend of ₹3 per equity share to commemorate its 90th anniversary

  • Bringing the total dividend to ₹16 per share (face value ₹2)

Cipla’s performance reflects resilience amid regulatory headwinds and a clear strategic focus on its core markets and growth drivers. As the company moves forward, emphasis will remain on scaling key markets, strengthening flagship brands, advancing its product pipeline, and resolving regulatory issues